ASCO GU 2018 Renal Cancer - Results from #20

Viewing 21-40 of 68 articles

ASCO GU 2018: Real World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

ASCO GU 2018: Conditional Survival and Landmark Analysis for Patients with Small Renal Masses Undergoing Active Surveillance at a Tertiary Care Center

ASCO GU 2018: Antibiotic Use and Outcomes with Systemic Therapy in Metastatic Renal Cell Carcinoma (mRCC)

ASCO GU 2018: Incidence and mortality of Renal Cell Carcinoma in the U.S.: A SEER-based Study Investigating Trends Over the Last Four Decades

ASCO GU 2018: Trends and Morbidity for Minimally Invasive Versus Open Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma

ASCO GU 2018: Renal Cell Carcinoma Primary Tumor Shrinkage on Vascular Endothelial Growth Factor Targeted Therapy - A Pooled Analysis

ASCO GU 2018: Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cell Cancer: Subgroup Analysis of the ASSURE (E2805) Trial

ASCO GU 2018:Oncologic and Functional Follow-up After Renal Mass Treatment

ASCO GU 2018: Interpreting Data on Renal Function Preservation After Nephrectomy: Has the EORTC Trial Put the Issue to Rest?

ASCO GU 2018: Impact of Metastatic Local Treatment in the Strategy of Metastatic Renal Cell Carcinoma Including Stereotactic Radiotherapy, Surgery, and Radiofrequency in an Expert Center.

ASCO GU 2018: Assessing The Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity (Q-TWiST) In Immuno-Oncology: An Application to Nivolumab vs. Everolimus in Previously Treated Advanced RCC

ASCO GU 2018: Comparing Cabozantinib Treatment for a Cohort of Patients with Metastatic Clear Cell RCC and Variant Histology RCC: A Retrospective Study

ASCO GU 2018: U-SMART: A Novel Scoring System of Preoperative Predictors to Stratify Oncologic Risk of Small Renal Mass

ASCO GU 2018: Can Health-Related Quality of Life Predict Conditional Survival in Metastatic RCC? Results from a Large Phase III Trial

ASCO GU 2018: Characterization of the Benefit-Risk Profile of Nivolumab + Ipilimumab Sunitinib for Treatment-Naïve Advanced RCC (Checkmate 214)

ASCO GU 2018: Outcomes of Patients with Metastatic Clear-Cell RCC Treated with Second-Line VEGFR-TKI After First-Line Immune Checkpoint Inhibitors

ASCO GU 2018: Outcomes of Metastatic Chromophobe Renal Cell Carcinoma with Sarcomatoid Features

ASCO GU 2018: Analysis of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma

ASCO GU 2018: Creation of a Tissue Expression Biomarker-augmented Prognostic Model for Patients with Metastatic Renal Cell Carcinoma

ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma

1
2
3
4